Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA

Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA® ) has been registered by the TGA

20 April 2015

MSD announced that its anti-PD1 immunotherapy pembrolizumab (trade name KEYTRUDA®) has been registered by the Therapeutic Goods Administration (TGA) for the treatment of the most deadly form of skin cancer – advanced metastatic melanoma. Australia is the first country in the world to register KEYTRUDA for the first line treatment of unresectable or metastatic melanoma in adults. This will change the future of treatments for all melanoma patients in Australia.

Associate Professor Georgina Long from Melanoma Institute of Australia (MIA) explained that Australian clinicians and institutes have been involved in the clinical trials of anti-PD1 for over three years.

“We are proud to have been involved in the development of this medicine and that hundreds of Australian patients with advanced melanoma have been treated with pembrolizumab. This drug is being investigated for use in other cancers. It is vital we continue to do research such as this to improve the outcomes for cancer patients.”

MIA and affiliates will continue to lobby on behalf of the Australian community to ensure anti-PD1 is added to the PBS which would make it accessible for all Australians with advanced melanoma without delay.

 
Evidence drives sweeping changes to melanoma treatment recommendations
25 May 2018

Evidence drives sweeping changes to melanoma treatment recommendations

Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.

Melanoma and Marital Status: A Study
11 May 2018

Melanoma and Marital Status: A Study

An American study has discovered a link between early detection and marital status in melanoma diagnosis. 

A weekend in Paris talking all things pathology...
02 May 2018

A weekend in Paris talking all things pathology...

An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.

Our own 'Australian Story'
30 Apr 2018

Our own 'Australian Story'

Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts. 

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
27 Apr 2018

Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma

For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.

The inspiring story of Emma Betts premieres on Australian Story
16 Apr 2018

The inspiring story of Emma Betts premieres on Australian Story

'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma. 

Toyota helps tackle Australia's national cancer - melanoma
09 Apr 2018

Toyota helps tackle Australia's national cancer - melanoma

Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.

Tackling the Kokoda Trail for melanoma
06 Apr 2018

Tackling the Kokoda Trail for melanoma

Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.

Professor Richard Scolyer presents at world's largest annual meeting of pathologists
29 Mar 2018

Professor Richard Scolyer presents at world's largest annual meeting of pathologists

Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.

Congratulations to Kaye Oakley
29 Mar 2018

Congratulations to Kaye Oakley

A round of applause for a well deserved win.

Farewell from Carole Renouf, CEO of Melanoma Institute Australia
26 Mar 2018

Farewell from Carole Renouf, CEO of Melanoma Institute Australia

A message from our CEO, Carole Renouf

Marching in the twilight
26 Mar 2018

Marching in the twilight

Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma. 

Researchers uncover treatment sequence for advanced melanoma patients
23 Mar 2018

Researchers uncover treatment sequence for advanced melanoma patients

Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.

An unsung hero of melanoma care for nearly 30 years
22 Mar 2018

An unsung hero of melanoma care for nearly 30 years

Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.

Sharing our research on melanoma surgery
21 Mar 2018

Sharing our research on melanoma surgery

MIA is sharing it's research with the global surgical oncology community this week at the Society of Surgical Oncology Annual Cancer Symposium.

14 Melanoma Marches down, 7 to go!
19 Mar 2018

14 Melanoma Marches down, 7 to go!

It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.

Melanoma March keeps marching
14 Mar 2018

Melanoma March keeps marching

Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.

Melanoma March kicks off for 2018
08 Mar 2018

Melanoma March kicks off for 2018

Melanoma Institute Australia's annual fundraising initiative is all systems go!

Calls for urgent crackdown on illegal backyard solariums
07 Mar 2018

Calls for urgent crackdown on illegal backyard solariums

The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma
28 Feb 2018

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier's march against melanoma

15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.